Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial

Jean-Eric Tarridea Department of Health Research Methods, Evidence, and Impact (HEI), Faculty of Health Sciences, McMaster University, Hamilton, CanadaCorrespondence[email protected]

Mansoor Husainb Ted Rogers Centre for Heart Research, Toronto General Hospital Research Institute, Toronto, Canada

Andreas Andersenc Biostatistics GLP-1 and CV 1, Novo Nordisk A/S, Søborg, Denmark

Jens Gundgaardd GEPA Early Asset Strategy, Novo Nordisk A/S, Søborg, Denmark

Maria Luckeviche Patient Access, Novo Nordisk Canada Inc., Mississauga, Canada

Thomas Markf Biostatistics Degludec, Novo Nordisk A/S, Søborg, Denmark

Lily Wagnerg Novo Nordisk A/S, Søborg, Denmark

Thomas R. Pieberh Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

show all

Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date